Neuphoria Therapeutics Inc.
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q3 | -0.09 | $0 | -$4M |
| 2025 Q2 | 0.41 | $0 | -$6M |
| 2025 Q1 | -6.67 | $0 | -$4M |
| 2025 Q4 | -4.65 | -$10M | $74M |
| 2025 Q3 | 6.55 | $15M | $11M |
| 2024 Q2 | -0.01 | $662,715 | -$3M |
| 2024 Q1 |
| -0.00 |
| $10M |
| -$4M |
| 2024 Q4 | -0.00 | $0 | -$3M |